Rheumatology

Back to articles

Oral spleen tyrosine kinase inhibitor benefits patients with RA

KEY POINT

In a study recently published in the New England Journal of Medicine, the oral spleen tyrosine kinase (Syk) inhibitor R788 significantly decreased disease activity in patients with active rheumatoid arthritis (RA).

SOURCES

Weinblatt ME et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303–12.

Recent Articles